Please assess the completion status of the following clinical trial:

Trial Title: Study Assessing the Effect of Medications to Prevent Fever on Prevenar 13®

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 2 months (56 to 98 days) at time of enrollment.~* Healthy infant as determined by medical history, physical examination, and judgment of the investigator.~Exclusion Criteria:~* Previous vaccination with licensed or investigational pneumococcal, diphtheria, tetanus, pertussis, polio, or Hib conjugate vaccines.~* A previous anaphylactic reaction to any vaccine or vaccine-related component.~* Allergy or contraindication to paracetamol or ibuprofen administration.~* Contraindication to vaccination with pneumococcal conjugate, diphtheria, tetanus, pertussis, polio, Hib, or HBV vaccines.

- Gender: ALL
- Minimum Age: 56 Days
- Maximum Age: 98 Days
- Healthy Volunteers: t

Study Arms:
- Group 1 (Type: EXPERIMENTAL): Subjects will receive 13-valent pneumococcal vaccine and INFANRIX hexa at 2, 3, 4 and 12 months of age. They will also receive 2 doses of paracetamol on the day of each vaccination.
- Group 2 (Type: EXPERIMENTAL): Subjects will receive 13-valent pneumococcal vaccine and INFANRIX hexa at 2, 3, 4 and 12 months of age. They will also receive 2 doses of ibuprofen on the day of each vaccination.the first dose.
- Group 3 (Type: EXPERIMENTAL): Subjects will receive 13-valent pneumococcal vaccine and INFANRIX hexa at 2, 3, 4 and 12 months of age. They will also receive 3 doses of paracetamol on the day of each vaccination.
- Group 4 (Type: EXPERIMENTAL): Subjects will receive 13-valent pneumococcal vaccine and INFANRIX hexa at 2, 3, 4 and 12 months of age. They will also receive 3 doses of ibuprofen on the day of each vaccination.
- Group 5 (Type: EXPERIMENTAL): Subjects will receive 13-valent pneumococcal vaccine and INFANRIX hexa at 2, 3, 4 and 12 months of age. This group does not receive any antipyretic medication as part of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).